IN8bio, Inc (NASDAQ: INAB): Our Biotech Focus Stock

IN8bio, Inc (NASDAQ: INAB) just released very enticing positive data from their phase 1 investigator-sponsored trial of INB-100 in Leukemia patients.

Related Keywords

India ,Chris Turnbull ,Sheikh Linkedin ,Michael Sheikh ,Bioxytran Inc ,Twitter ,Oral Galectin Inhibitor ,Controlled Trial ,Commercial Officer Michael Sheikh ,Galectin Therapeutics ,Galecto Bioscience ,Sleuthing Sheikh ,Emerging Growth ,Pound Comparison ,Featured ,Zainab ,